HASBROUCK HEIGHTS, N.J., Nov. 1, 2012 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce that Paul Averback, CEO, will be making a presentation today about the Company and its prospects at the Singular Research seventh annual "Best of the Uncovereds" Conference at the Luxe Sunset Boulevard Hotel in Los Angeles.
Nymox Pharmaceutical Corporation is engaged in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. The Company's lead drug candidate, NX-1207, is currently in late stage Phase 3 clinical trial development in the U.S. for the treatment of benign prostatic hyperplasia (BPH), a common condition of older men associated with growth in prostate size as men age. The company recently initiated a Phase 2 clinical trial of NX-1207 for the treatment of low grade localized prostate cancer. More information about Nymox is available at www.nymox.com, email: email@example.com, or 800-936-9669.
About Singular Research
Singular Research aims to be the most trusted supplier of independent, single-source research on small-to-micro cap companies to serve the small-to-medium sized equity manager including Hedge Fund managers. Singular provides initiation reports and quarterly updates for 30 to 60 companies and makes recommendations. Singular's independent analysts have no financial interest in the stocks they cover. Analysts are compensated based on the accuracy of their research calls not through trading commissions or potential deal flow. Singular's coverage list performance since inception, August 2004, is positive 198.3% through September 2012, compared to 31.1% for the S&P 500 and 51.6% for the Russell 2000.
For more information about Singular Research, visit http://www.singular-research.com. For more information about the conference, please contact Robert Maltbie, CFA, Singular Research, 818-222-6915, firstname.lastname@example.org.
This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Development of drug products involves substantial risks and actual results may differ materially from expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
CONTACT: Roy Wolvin
Nymox Pharmaceutical Corporation